- Home
- CERT vs KOD Comparison
CERT vs KOD Comparison
Compare CERT & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CERT | KOD |
|---|---|---|
| Founded | 2008 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CERT | KOD |
|---|---|---|
| Price | $9.45 | $27.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 7 |
| Target Price | $12.78 | ★ $26.57 |
| AVG Volume (30 Days) | ★ 2.0M | 1.1M |
| Earning Date | 02-25-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $415,551,000.00 | N/A |
| Revenue This Year | $10.75 | N/A |
| Revenue Next Year | $6.32 | N/A |
| P/E Ratio | $140.59 | ★ N/A |
| Revenue Growth | ★ 11.47 | N/A |
| 52 Week Low | $8.03 | $1.92 |
| 52 Week High | $15.69 | $31.18 |
Technical Indicators
Market Signals| Indicator | CERT | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 55.10 | 53.49 |
| Support Level | $9.06 | $26.32 |
| Resistance Level | $9.45 | $29.38 |
| Average True Range (ATR) | 0.31 | 2.08 |
| MACD | 0.06 | -0.24 |
| Stochastic Oscillator | 67.49 | 53.69 |
Price Performance
Historical ComparisonAbout CERT Certara Inc.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.